Search Bar & Filters
Found 19 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a drug called brenipatide when added to standard treatment for adults with major depressive disorder. The study compares brenipatide plus standard care to a placebo plus standard care to see if it can delay the return of major depressive symptoms. This is a phase 3, randomized, double-blind trial sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all given by subcutaneous injection along with their standard care. The study has four periods a screening phase lasting about one month, a combined treatment and post-treatment phase lasting at least 12 months, and a safety follow-up period of about two months. The total participation time may vary and can be shortened if symptoms worsen or if participants withdraw. During the study, participants will self-inject the study medication and keep electronic and paper diaries, complete questionnaires, and attend scheduled visits. Researchers will measure the time to relapse of major depressive disorder symptoms as the main outcome. Other assessments include changes in body weight, depression severity, functional impairment, anxiety levels, quality of life, and presence of treatment-related antibodies. Safety monitoring will continue throughout the study and follow-up periods.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide alongside standard of care SoC compared to a placebo plus SoC in adult participants with major depressive disorder. This Phase 3 trial aims to delay the return of major depressive symptoms and is sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all administered by subcutaneous injection in addition to their standard treatment. The study includes a screening period lasting about one month, followed by a treatment period and potential post-treatment phase that together last at least 12 months. Throughout the trial, participants will self-inject the study medication and complete electronic and paper diaries along with questionnaires. Researchers will monitor the time to relapse of major depressive disorder and assess changes in depression rating scales, body weight, functional impairment, anxiety, quality of life, and other patient-reported outcomes. The follow-up period after treatment will last approximately 2 months.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide combined with standard treatment compared to placebo with standard treatment in adults with schizophrenia. This phase 2 study aims to understand how brenipatide affects body weight and other clinical measures in this population. The trial is sponsored by Eli Lilly and Company and includes adults aged 18 to 55 years diagnosed with schizophrenia. Participants will be randomly assigned to receive either brenipatide or placebo, both administered by subcutaneous injection alongside their usual schizophrenia care. The study is double-blind, meaning neither participants nor researchers will know who receives the active drug or placebo. The trial consists of three periods a screening period of about one month, a treatment period lasting up to 12 months, and a follow-up period of approximately two months. During the study, participants will attend regular visits for assessments including body weight changes, cognitive testing, symptom severity scales, and functional capacity evaluations. Researchers will also monitor safety through laboratory tests and measure drug levels and immune responses. The total participation time may be up to 15 months, including screening, treatment, and follow-up to evaluate outcomes and safety comprehensively.
Actively Recruiting
Researchers are exploring new treatment options for people with advanced colorectal cancer that has spread or cannot be removed by surgery. This cancer type, affecting the colon or rectum, sometimes involves problems with the bodys DNA repair system called dMMR or a condition called MSI. These issues can cause cancer cells to rely on a protein called Werner helicase to survive. Blocking this protein might help stop cancer growth with less harm to healthy cells. This Phase 2 study evaluates a drug named VVD-133214 that blocks Werner helicase, combined with pembrolizumab, an immunotherapy drug approved to help the immune system attack cancer cells. Participants in this trial will receive oral VVD-133214 along with pembrolizumab given by intravenous infusion every three weeks. The study compares this combination to pembrolizumab alone to find the best dose of VVD-133214 and to assess whether the combination works better. Participants will receive VVD-133214 as long as it remains helpful without causing serious side effects, while pembrolizumab treatment will continue for up to two years. Participants may stop treatment at any time. During the trial, participants will have regular visits for tests, scans, and health check-ups to monitor how their cancer responds and to track any new or worsening medical problems. After stopping treatment, follow-up visits will occur 30 days after the last VVD-133214 dose and 100 days after the last pembrolizumab dose. Long-term follow-up visits will continue every 90 days as long as participants agree to remain in the study. The main outcome measured is the progression-free survival rate at six months, with safety and other response measures also monitored throughout up to about 36 months.
Actively Recruiting
Researchers are evaluating the effectiveness of osavampator compared to a placebo as an additional treatment to delay the return of depressive symptoms in adults with major depressive disorder MDD. This Phase 3 study focuses on maintaining treatment effects in participants diagnosed with recurrent moderate or severe MDD or persistent depressive disorder who have not responded adequately to oral antidepressants. The study aims to understand whether osavampator can help prevent relapse in this population. Participants will first receive osavampator during an initial open-label treatment phase. Following this, they will be randomly assigned to receive either osavampator or a matching placebo during a double-blind maintenance period. Both treatments are given as oral tablets, and participants will continue their existing oral antidepressants at the same dose and frequency throughout the study. The study may last up to approximately 32 months from randomization. During the study, participants will be regularly monitored for relapse of depressive symptoms using the Hamilton Depression Rating Scale. Researchers will track the time from randomization to relapse or the end of the study to assess treatment maintenance. Safety and adherence will be evaluated throughout, with participants expected to comply with study procedures and restrictions. The total duration of participation varies but can extend up to nearly three years.
Actively Recruiting
Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.
Actively Recruiting
Researchers are evaluating the combination of CVM-1118, a new small molecule anti-cancer drug, with nivolumab, an immune checkpoint inhibitor, in people with unresectable advanced hepatocellular carcinoma HCC. This phase 2 study aims to further investigate the effectiveness of this combination treatment after safety was established in earlier studies. The trial focuses on HCC that cannot be removed by surgery and has progressed despite prior therapies, addressing a significant need for advanced liver cancer care. Participants receive nivolumab intravenously every two weeks at 240 mg, with an option to increase to 480 mg every four weeks from cycle 3 based on safety and tolerability. CVM-1118 is given orally twice daily starting at 200 mg, with a possible increase to 300 mg twice daily after safety assessment. Treatment cycles last 28 days and continue until disease progression, unacceptable side effects, or withdrawal of consent. During the study, participants undergo regular assessments including imaging scans to measure tumor response, laboratory tests, vital sign monitoring, and evaluation of side effects. The main outcome is the objective response rate measured 24 weeks after the last participant begins CVM-1118. Secondary outcomes include duration of response, progression-free and overall survival, safety assessments, and drug concentration levels. Follow-up continues for up to one year after the last dose to monitor long-term effects and safety.
Actively Recruiting
Researchers are evaluating a Dyadic Co-learning Intervention designed for patients with prostate cancer and their spouses to help them better cope with the challenges of cancer. This study aims to improve physical symptoms, emotional well-being, and resilience through shared learning and support. The trial uses a randomized controlled design to compare routine care alone with routine care plus the new co-learning program. Participants will be randomly assigned to either a control group receiving routine care or an experimental group receiving routine care plus an 8-week Dyadic Co-learning Intervention. This intervention includes a co-learning handbook, a mobile app, and professional support. The program encourages patients and their spouses to learn and support each other together over the course of 8 weeks. Participants will complete questionnaires at the start of the study, and again at 10 and 16 weeks after baseline to measure outcomes such as family resilience, physical symptoms, fatigue, loneliness, subjective well-being, and satisfaction with the intervention. The study monitors both patients and spouses to assess the interventions effects on their health and well-being over time.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating two educational approaches to improve the use of the My Health Bank App, a personal health record system in Taiwan, among adults aged 50 and older. The study aims to address the digital divide faced by older adults by comparing the effectiveness of intensive guided learning versus flexible self-study using AI-co-created educational materials. The trial is designed as a randomized controlled study to assess improvements in digital health literacy, self-efficacy, and app usage behavior. The study is conducted over 18 months and divided into three phases. The first phase involves developing AI-collaborative educational materials and testing their feasibility in a pilot trial. The second phase enrolls participants in a formal randomized controlled trial where they are assigned to either an intensive guided learning group with instructor support or a flexible self-study group using the same materials independently. The final phase focuses on data analysis and reporting. Both groups use the My Health Bank App and educational content designed to enhance digital health skills. Participants will undergo assessments at baseline, one week, and four weeks post-intervention, including measurements of eHealth literacy and general self-efficacy. Researchers will track changes in these scores and app usage behavior to evaluate the interventions. The study includes cognitive screening and monitoring of participants ability to install and use the app. Data will be collected and analyzed to identify effective strategies for improving digital health management among adults over 50.
Actively Recruiting
This research aims to evaluate how two different virtual reality-based preoperative education methods affect anxiety, learning, self-care ability, and cognitive load in patients undergoing urolithiasis surgery. The trial compares routine education, standard virtual reality education, and an enhanced two-tier virtual reality education approach. The study addresses common preoperative anxiety and aims to improve patient preparation using immersive, interactive VR technology combined with knowledge testing and feedback. Participants are randomly assigned to one of three groups routine preoperative education provided by nursing staff, standard virtual reality education featuring immersive 360-degree content about the surgery and self-care, or two-tier virtual reality education that adds interactive questioning and feedback to improve understanding and engagement. These educational interventions are delivered before the urolithiasis surgery. During the study, participants anxiety levels are measured before and after the intervention and on the first day after surgery using established anxiety scales. Knowledge about urolithiasis surgery, self-care abilities, and cognitive load are also assessed at various points. The study monitors how well patients learn and manage self-care and tracks their anxiety through the perioperative period. Participation involves completing questionnaires and using virtual reality equipment before surgery.
1-10 of 19
1